**Supplementary table 1. Proportions of migrants and Finnish-born participants who discontinued medication (n=535) by background variables**

|  |  |  |
| --- | --- | --- |
|  | **Migrant % (n)** | **Finnish % (n)** |
| **Sex** |  |  |
| Female | 55.5 (147) | 44.1 (119) |
| Male | 44.5 (118) | 55.9 (151) |
| **Age** |  |  |
| 15­-29 | 41.7 (110) | 49.6 (133) |
| 30-44 | 33.0 (87) | 30.6 (82) |
| 45-59 | 19.7 (52) | 15.7 (42) |
| 60 or more | 5.7 (15) | 4.1 (11) |
| **Marital status** |  |  |
| Married / registered | 38.5 (102) | 16.3 (44) |
| Unmarried  | 28.7 (76) | 73.3 (198) |
| Widowed/divorced/separated | 32.8 (87) | 10.4 (28) |
| **SES** |  |  |
| Entrepreneurs | 4.1 (9) | 3.1 (8) |
| Higher white collar | 5.9 (13) | 5.1 (13) |
| Lower white collar | 8.7 (19) | 23.5 (60) |
| Blue collar | 20.1 (44) | 12.2 (31) |
| Others | 61.2 (134) | 56.1 (143) |
|  |  |  |
| **Antipsychotic treatment before diagnosis** |  |  |
| Yes | 5.7 (15) | 13.3 (36) |
| No | 94.3 (250) | 86.7 (234) |
| **First antipsychotic (ref olanzapine)** |  |  |
| Olanzapine | 32.8 (87) | 23.0 (62) |
| Quetiapine | 23.4 (62) | 32.6 (88) |
| Risperidone | 25.7 (68) | 24.8 (67) |
| Aripiprazole | 1.1 (3) | 3.0 (8) |
| Clozapine | 1.5 (4) | 1.9 (5) |
| Other monotherapy | 28 (10.6) | 21 (7.8) |
| Polytherapy | 4.9 (13) | 7.0 (19) |
| **First diagnosed**  |  |  |
| In hospital | 54.7 (145) | 44.8 (121) |
| In outpatient care | 45.3 (120) | 55.2 (149) |
| **Involuntary hospitalization**  |  |  |
| Yes | 22.3 (59) | 24.8 (67) |
| No | 77.7 (206) | 75.2 (203) |
| **Diagnosis during first year** |  |  |
| F20/F25 | 13.6 (265) | 21.1 (57) |
| Other | 86.4 (229) | 78.99 (213) |

**Supplementary Table 2. Risk of antipsychotic medication discontinuation assessed with Cox regression analysis. Unadjusted and adjusted hazard ratios. Antipsychotic treatment before diagnosis included in the covariates.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HR (95 % CI)** | **aHR1 (95 % CI)** | **aHR2 (95 % CI)** |
| **Migrant status (ref Finnish)** |  |  |  |
| Migrant | **1.53 (1.32-1.77)** | **1.37 (1.16-1.61)** | **1.19 (1.00-1.41)** |
| **Region of origin (ref Finland)** |  |  |  |
| EU/EFTA, North America or Australia | **1.29 (1.02-1.65)** | 1.23 (0.96-1.57) | 1.11 (0.86-1.43) |
| Russia and Eastern Europe | **1.36 (1.10-1.68)** | 1.22 (0.98-1.53) | 1.05 (0.83-1.32) |
| North Africa and Middle East | **2.01 (1.53-2.65)** | **1.94 (1.45-2.59)** | **1.62 (1.21-2.17)** |
| Sub-Saharan Africa | **2.05 (1.51-2.80)** | **1.70 (1.23-2.35)** | 1.39 (1.00-1.93) |
| Asia | **1.58 (1.16-2.14)** | 1.31 (0.94-1.82) | 1.11 (0.80-1.55) |
| **Time since migration (ref Finnish)** |  |  |  |
| Less than 5 years | **1.80 (1.46-2.23)** | **1.42 (1.11-1.81)** | 1.18 (0.92-1.52) |
| 5-15 years | **1.57 (1.28-1.91)** | **1.40 (1.13-1.73)** | 1.17 (0.95-1.46) |
| More than 15 years | **1.36 (1.09-1.71)** | **1.33 (1.05-1.69)** | 1.18 (0.93-1.51) |
|  |  |  |  |
| **Sex (ref male)** |  |  |  |
| Female | 1.11 (0.96-1.29) | 1.08 (0.93-1.25) | 1.01 (0.87-1.18) |
| **Age (ref 60 or more)** |  |  |  |
| 15­-29 | **1.60 (1.13-2.29)** | **2.06 (1.43-2.97)** | **1.51 (1.03-2.20)** |
| 30-44 | 0.99 (0.69-1.42) | 1.11 (0.77-1.60) | 1.05 (0.73-1.52) |
| 45-59 | 0.83 (0.57-1.22) | 0.87 (0.60-1.27) | 0.94 (0.64-1.38) |
| **Marital status (ref widowed/divorced/separated)** |  |  |  |
| Married/registered  | 1.13 (0.92-1.39) | 1.09 (0.88-1.34) | 1.04 (0.84-1.29) |
| Unmarried | 0.85 (0.70-1.02) | **0.66 (0.53-0.81)** | **0.77 (0.62-0.95)** |
| **SES (ref entrepreneurs)** |  |  |  |
| Higher white collar | 0.91 (0.55-1.50) | 0.83 (0.50-1.38) | 1.01 (0.61-1.69) |
| Lower white collar | 1.19 (0.76-1.84) | 1.16 (0.74-1.82) | 1.39 (0.88-2.20) |
| Blue collar | 0.99 (0.64-1.53) | 0.92 (0.59-1.42) | 1.19 (0.76-1.85) |
| Others | 0.75 (0.50-1.13) | 0.81 (0.54-1.23) | 1.24 (0.82-1.89) |
|  |  |  |  |
| **Antipsychotic treatment before diagnosis (ref yes)** |  |  |  |
| No treatment | **4.85 (3.79-6.21)** | **4.19 (3.25-5.40)** | **3.31 (2.54-4.30)** |
| **First antipsychotic (ref olanzapine)** |  |  |  |
| Quetiapine | 0.97 (0.80-1.18) | 1.00 (0.82-1.22) | 1.06 (0.87-1.30) |
| Risperidone | 0.99 (0.81-1.21) | 1.11 (0.90-1.36) | 1.10 (0.89-1.35) |
| Aripiprazole | 0.82 (0.51-1.32) | 0.86 (0.53-1.37) | 0.93 (0.58-1.49) |
| Clozapine | **0.18 (0.10-0.31)** | **0.22 (0.13-0.39)** | **0.49 (0.27-0.87)** |
| Other monotherapy | **0.52 (0.39-0.68)** | **0.65 (0.49-0.87)** | 0.83 (0.62-1.11) |
| Polytherapy | **0.55 (0.38-0.80)** | **0.61 (0.42-0.88)** | **0.65 (0.45-0.95)** |
| **First diagnosed (ref in hospital)** |  |  |  |
| In outpatient care | 0.90 (0.78-1.05) | 0.98 (0.84-1.14) | 1.13 (0.97-1.31) |
| **Involuntary hospitalization (ref no)** |  |  |  |
| Yes | **1.67 (1.39-2.01)** | **1.67 (1.38-2.01)** | **1.52 (1.26-1.83)** |
| **Diagnosis during first year (ref F20/F25)** |  |  |  |
| Other | **2.08 (1.71-2.54)** | **1.84 (1.50-2.25)** | **1.42 (1.15-1.74)** |

1 Adjusted for sex, age and marital status

2 Adjusted for sex, age, marital status, antipsychotic treatment before diagnosis, first antipsychotic, involuntary hospitalization and diagnosis during first year

**Supplementary table 4. Risk of antipsychotic medication discontinuation assessed with Cox regression analysis. Stratified analysis for migrants and Finnish-born participants. Unadjusted and adjusted hazard ratios. Antipsychotic treatment before diagnosis included in the covariates.**

|  |  |  |
| --- | --- | --- |
|  | **Migrants** | **Finnish-born participants** |
|  | **HR (95 % CI)** | **aHR1 (95 % CI)** | **aHR2 (95 % CI)** | **HR (95 % CI)** | **aHR1 (95 % CI)** | **aHR2 (95 % CI)** |
|  |  |  |  |  |  |  |
| **Region of origin (ref EU/EFTA, North America or Australia)** |  |  |  |  |  |  |
| Russia and Eastern Europe | 1.06 (0.80-1.41) | 0.99 (0.74-1.32) | 0.93 (0.70-1.25) |  |  |  |
| North Africa and Middle East | **1.56 (1.12-2.18)** | **1.61 (1.14-2.26)** | **1.50 (1.06-2.12)** |  |  |  |
| Sub-Saharan Africa | **1.63 (1.12-2.35)** | 1.45 (1.00-2.11) | 1.25 (0.86-1.83) |  |  |  |
| Asia | 1.23 (0.86-1.77) | 1.09 (0.75-1.59) | 1.04 (0.72-1.52) |  |  |  |
| **Time since migration (ref more than 15 years)** |  |  |  |  |  |  |
| Less than 5 years | **1.33 (1.01-1.75)** | 1.12 (0.83-1.51) | 1.06 (0.78-1.43) |  |  |  |
| 5-15 years | 1.15 (0.88-1.50) | 1.06 (0.81-1.40) | 1.00 (0.76-1.32) |  |  |  |
|  |  |  |  |  |  |  |
| **Sex (ref male)** |  |  |  |  |  |  |
| Female | 1.12 (0.91-1.38) | 1.14 (0.92-1.41) | 0.97 (0.78-1.20) | 1.04 (0.84-1.28) | 1.02 (0.82-1.26) | 1.02 (0.82-1.27) |
| **Age (ref 60 or more)** |  |  |  |  |  |  |
| 15­-29 | 1.41 (0.86-2.30) | 1.66 (1.00 -2.75) | 1.16 (0.68-1.98) | **1.84 (1.10-3.08)** | **2.16 (1.26-3.70)** | 1.64 (0.94-2.89) |
| 30-44 | 0.98 (0.60-1.62) | 1.03 (0.62-1.70) | 0.82 (0.49-1.39) | 1.04 (0.62-1.75) | 1.12 (0.66-1.91) | 1.19 (0.69-2.06) |
| 45-59 | 0.80 (0.48-1.33) | 0.80 (0.48-1.34) | 0.74 (0.43-1.25) | 0.79 (0.45-1.39) | 0.83 (0.47-1.47) | 1.07 (0.60-1.92) |
| **SES (ref entrepreneurs)** |  |  |  |  |  |  |
| Higher white collar | 0.85 (0.42-1.70) | 0.78 (0.39-1.56) | 0.92 (0.45-1.88) | 0.98 (0.47-2.08) | 0.88 (0.42-1.88) | 0.99 (0.46-2.13) |
| Lower white collar | 1.17 (0.63-2.20) | 1.12 (0.59-2.13) | 1.26 (0.66-2.44) | 1.25 (0.64-2.43) | 1.18 (0.60-2.32) | 1.28 (0.65-2.54) |
| Blue collar | 1.15 (0.65-2.02) | 1.10 (0.62-1.94) | 1.24 (0.69-2.23) | 0.86 (0.44-1.70) | 0.77 (0.39-1.52) | 1.05 (0.52-2.11) |
| Others | 0.99 (0.58-1.67) | 0.99 (0.57-1.69) | 1.31 (0.75-2.28) | 0.63 (0.33-1.20) | 0.67 (0.35-1.29) | 1.05 (0.54-2.03) |
| **Marital status (ref widowed/divorced/separated)** |  |  |  |  |  |  |
| Married/registered  | 1.02 (0.80-1.30) | 0.99 (0.77-1.28) | 0.90 (0.70-1.17) | 1.43 (0.96-2.13) | 1.39 (0.92-2.10) | 1.40 (0.92-2.13) |
| Unmarried | 0.94 (0.72-1.23) | **0.74 (0.55-0.99)** | 0.81 (0.59-1.10) | 1.16 (0.83-1.62) | 0.86 (0.60-1.25) | 0.92 (0.63-1.33) |
|  |  |  |  |  |  |  |
| **Antipsychotic treatment before diagnosis (ref yes)** |  |  |  |  |  |  |
| No treatment | **4.24 (2.81-6.38)** | **3.96 (2.57-6.09)** | **3.64 (2.33-5.68)** | **4.81 (3.53-6.57)** | **4.16 (3.03-5.72)** | **3.14 (2.26-4.37)** |
| **First antipsychotic (ref olanzapine)** |  |  |  |  |  |  |
| Quetiapine | 0.87 (0.65-1.15) | 0.94 (0.70-1.25) | 0.91 (0.68-1.21) | 1.15 (0.87-1.52) | 1.09 (0.83-1.45) | 1.23 (0.93-1.63) |
| Risperidone | 0.87 (0.66-1.14) | 0.96 (0.72-1.28) | 0.93 (0.70-1.24) | 1.14 (0.84-1.53) | 1.27 (0.93-1.72) | 1.27 (0.94-1.72) |
| Aripiprazole | 0.88 (0.41-1.88) | 0.88 (0.41-1.90) | 1.00 (0.46-2.17) | 0.91 (0.50-1.67) | 0.90 (0.49-1.65) | 0.96 (0.52-1.78) |
| Clozapine | **0.25 (1.12-0.55)** | **0.31 (0.14-0.67)** | 0.54 (0.25-1.19) | **0.15 (0.06-0.34)** | **0.17 (0.07-0.39)** | **0.41 (0.17-0.97)** |
| Other monotherapy | 0.71 (0.49-1.03) | 0.88 (0.60-1.29) | 1.15 (0.78-1.70) | **0.42 (0.28-0.65)** | **0.52 (0.33-0.80)** | **0.63 (0.41-0.99)** |
| Polytherapy | 0.62 (0.35-1.11) | 0.63 (0.36-1.12) | 0.62 (0.35-1.10) | **0.59 (0.36-0.96)** | 0.64 (0.39-1.04) | 0.71 (0.44-1.16) |
| **First diagnosed (ref in hospital)** |  |  |  |  |  |  |
| In outpatient care | 0.95 (0.77-1.17) | 1.05 (0.85-1.31) | 1.14 (0.92-1.42) | 0.93 (0.75-1.14) | 0.98 (0.79-1.21) | 1.20 (0.96-1.49) |
| **Involuntary hospitalization (ref no)** |  |  |  |  |  |  |
| Yes | **1.45 (1.12-1.87)** | **1.52 (1.17-1.97)** | **1.53 (1.17-1.99)** | **1.84 (1.40-2.40)** | **1.80 (1.37-2.36)** | **1.56 (1.18-2.06)** |
| **Diagnosis during first year (ref F20/F25)** |  |  |  |  |  |  |
| Other | **1.65 (1.24-2.21)** | **1.62 (1.21-2.18)** | **1.45 (1.07-1.96)** | **2.28 (1.74-3.00)** | **1.99 (1.51-2.62)** | **1.39 (1.05-1.84)** |

1 Adjusted for sex, age and marital status

2 Adjusted for sex, age, marital status, antipsychotic treatment before diagnosis, first antipsychotic, involuntary hospitalization and diagnosis during first year

Bold font indicates statistical significance (p<0.05)

**Supplementary Table 4. Risk of antipsychotic medication discontinuation assessed with Cox regression analysis. Unadjusted and adjusted hazard ratios. Only participants without preceding use of antipsychotic included.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HR (95 % CI)** | **aHR1 (95 % CI)** | **aHR2 (95 % CI)** |
| **Migrant status (ref Finnish)** |  |  |  |
| Migrant | **1.26 (1.08-1.47)** | **1.25 (1.04-1.49)** | **1.23 (1.03-1.48)** |
| **Region of origin (ref Finland)** |  |  |  |
| EU/EFTA, North America or Australia | 1.19 (0.92-1.53) | 1.19 (0.91-1.55) | 1.14 (0.87-1.49) |
| Russia and Eastern Europe | 1.07 (0.86-1.34) | 1.08 (0.85-1.36) | 1.08 (0.85-1.37) |
| North Africa and Middle East | **1.75 (1.32-2.32)** | **1.81 (1.34-2.44)** | **1.73 (1.28-2.34)** |
| Sub-Saharan Africa | **1.49 (1.09-2.04)** | **1.47 (1.05-2.05)** | **1.44 (1.03-2.01)** |
| Asia | 1.23 (0.90-1.69) | 1.21 (0.86-1.70) | 1.19 (0.84-1.66) |
| **Time since migration (ref Finnish)** |  |  |  |
| Less than 5 years | **1.32 (1.06-1.65)** | 1.24 (0.96-1.61) | 1.21 (0.94-1.58) |
| 5-15 years | **1.26 (1.02-1.55)** | 1.24 (0.99-1.56) | 1.22 (0.97-1.53) |
| More than 15 years | 1.22 (0.96-1.54) | 1.23 (0.96-1.58) | 1.23 (0.95-1.58) |
|  |  |  |  |
| **Sex (ref male)** |  |  |  |
| Female | 1.02 (0.87-1.19) | 1.02 (0.87-1.19) | 0.97 (0.83-1.14) |
| **Age (ref 60 or more)** |  |  |  |
| 15­-29 | 1.29 (0.86-1.94) | 1.46 (0.95-2.23) | **1.65 (1.07-2.55)** |
| 30-44 | 1.02 (0.67-1.55) | 1.05 (0.69-1.60) | 1.18 (0.77-1.80) |
| 45-59 | 0.96 (0.62-1.48) | 0.97 (0.63-1.51) | 1.10 (0.71-1.72) |
| **Marital status (ref widowed/divorced/separated)**  |  |  |  |
| Married  | 1.13 (0.90-1.41) | 1.12 (0.89-1.40) | 1.06 (0.85-1.33) |
| Unmarried | 1.00 (0.82-1.22) | 0.86 (0.69-1.08) | 0.82 (0.66-1.03) |
| **SES (ref entrepreneurs)** |  |  |  |
| Higher white collar | 1.01 (0.60-1.70) | 1.00 (0.59-1.69) | 1.05 (0.62-1.79) |
| Lower white collar | 1.40 (0.89-2.21) | 1.44 (0.90-2.29) | 1.49 (0.93-2.39) |
| Blue collar | 1.19 (0.76-1.87) | 1.18 (0.75-1.86) | 1.31 (0.83-2.08) |
| Others | 1.17 (0.76-1.78) | 1.21 (0.78-1.86) | 1.34 (0.86-2.07) |
|  |  |  |  |
| **First antipsychotic (ref olanzapine)** |  |  |  |
| Quetiapine | 0.97 (0.79-1.20) | 1.00 (0.81-1.23) | 1.04 (0.84-1.28) |
| Risperidone | 1.01 (0.82-1.25) | 1.08 (0.87-1.34) | 1.11 (0.90-1.38) |
| Aripiprazole | 0.99 (0.62-1.59) | 0.97 (0.61-1.56) | 1.01 (0.63-1.63) |
| Clozapine | **0.31 (0.11-0.83)** | **0.30 (0.11-0.81)** | **0.36 (0.12-0.98)** |
| Other monotherapy | 0.77 (0.57-1.04) | 0.83 (0.61-1.14) | 0.91 (0.66-1.23) |
| Polytherapy | **0.65 (0.44-0.96)** | **0.66 (0.45-0.98)** | 0.68 (0.46-1.00) |
| **First diagnosed (ref in hospital)** |  |  |  |
| In outpatient care | **1.20 (1.02-1.40)** | **1.22 (1.05-1.43)** | 1.13 (0.97-1.33) |
| **Involuntary hospitalization (ref no)** |  |  |  |
| Yes | **1.38 (1.13-1.67)** | **1.39 (1.15-1.70)** | **1.46 (1.20-1.78)** |
| **Diagnosis during first year (ref F20/F25)** |  |  |  |
| Other | **1.67 (1.32-2.10)** | **1.64 (1.29-2.07)** | **1.65 (1.30-2.09)** |

1 Adjusted for sex, age and marital status

2 Adjusted for sex, age, marital status, antipsychotic treatment before diagnosis, first antipsychotic, involuntary hospitalization and diagnosis during first year

Bold font indicates statistical significance (p<0.05)

**Supplementary Table 5. Risk of antipsychotic medication discontinuation assessed with Cox regression analysis. Stratified analysis for migrants and Finnish-born participants. Unadjusted and adjusted hazard ratios. Only participants without preceding use of antipsychotic included.**

|  |  |  |
| --- | --- | --- |
|  | **Migrants** | **Finnish-born participants** |
|  | **HR (95 % CI)** | **aHR1 (95 % CI)** | **aHR2 (95 % CI)** | **HR (95 % CI)** | **aHR1 (95 % CI)** | **aHR2 (95 % CI)** |
| **Region of origin (ref EU/EFTA, North America or Australia)** |  |  |  |  |  |  |
| Russia and Eastern Europe | 0.91 (0.68-1.23) | 0.91 (0.67-1.22) | 0.95 (0.70-1.29) |  |  |  |
| North Africa and Middle East | **1.49 (1.05-2.11)** | **1.54 (1.08-2.20)** | **1.55 (1.08-2.21)** |  |  |  |
| Sub-Saharan Africa | 1.29 (0.89-1.87) | 1.27 (0.87-1.87) | 1.27 (0.86-1.87) |  |  |  |
| Asia | 1.05 (0.72-1.53) | 1.04 (0.71-1.53) | 1.09 (0.74-1.60) |  |  |  |
| **Time since migration (ref more than 15 years)** |  |  |  |  |  |  |
| Less than 5 years | 1.09 (0.82-1.44) | 1.02 (0.75-1.39) | 1.02 (0.75-1.40) |  |  |  |
| 5-15 years | 1.04 (0.79-1.37) | 1.02 (0.77-1.35) | 1.01 (0.76-1.34) |  |  |  |
|  |  |  |  |  |  |  |
| **Sex (ref male)** |  |  |  |  |  |  |
| Female | 0.95 (0.76-1.18) | 0.98 (0.78-1.22) | 0.93 (0.74-1.16) | 1.02 (0.81-1.27) | 1.01 (0.80-1.27) | 0.98 (0.77-1.24) |
| **Age (ref 60 or more)** |  |  |  |  |  |  |
| 15­-29 | 1.20 (0.68-2.13) | 1.24 (0.68-2.25) | 1.27 (0.69-2.33) | 1.41 (0.79-2.54) | 1.43 (0.76-2.71) | 1.72 (0.90-3.30) |
| 30-44 | 0.93 (0.52-1.65) | 0.92 (0.51-1.65) | 0.91 (0.50-1.66) | 1.12 (0.61-2.03) | 1.09 (0.58-2.03) | 1.30 (0.69-2.48) |
| 45-59 | 0.92 (0.51-1.67) | 0.92 (0.51-1.66) | 0.85 (0.46-1.58) | 0.92 (0.48-1.75) | 0.89 (0.46-1.73) | 1.21 (0.61-2.37) |
| **SES (ref entrepreneurs)** |  |  |  |  |  |  |
| Higher white collar | 0.92 (0.45-1.85) | 0.90 (0.44-1.83) | 0.99 (0.44-1.87) | 1.14 (0.50-2.58) | 1.09 (0.48-2.51) | 1.15 (0.50-2.68) |
| Lower white collar | 1.34 (0.71-2.51) | 1.32 (0.70-2.52) | 1.26 (0.65-2.45) | 1.55 (0.74-3.22) | 1.54 (0.73-3.26) | 1.53 (0.72-3.27) |
| Blue collar | 1.25 (0.71-2.20) | 1.22 (0.69-2.17) | 1.28 (0.72-2.31) | 1.15 (0.54-2.43) | 1.11 (0.52-2.37) | 1.27 (0.59-2.75) |
| Others | 1.28 (0.75-2.17) | 1.28 (0.74-2.20) | 1.35 (0.77-2.34) | 1.11 (0.55-2.27) | 1.12 (0.54-2.31) | 1.22 (0.59-2.56) |
| **Marital status (ref widowed/divorced/separated)** |  |  |  |  |  |  |
| Married  | 1.07 (0.82-1.38) | 1.05 (081-1.36) | 0.95 (0.73-1.24) | 1.30 (0.84-2.03) | 1.35 (0.85-2.15) | 1.31 (0.82-2.09) |
| Unmarried | 1.12 (0.85-1.47) | 0.94 (0.68-1.30) | 0.88 (0.63-1.23) | 1.19 (0.83-1.72) | 1.06 (0.70-1.61) | 0.98 (0.64-1.49) |
|  |  |  |  |  |  |  |
| **First antipsychotic (ref olanzapine)** |  |  |  |  |  |  |
| Quetiapine | 0.84 (0.63-1.12) | 0.89 (0.66-1.20) | 0.91 (0.68-1.23) | 1.16 (0.86-1.57) | 1.12 (0.83-1.52) | 1.20 (0.89-1.62) |
| Risperidone | 0.86 (0.65-1.14) | 0.92 (0.68-1.23) | 0.94 (0.70-1.26) | 1.21 (0.88-1.66) | 1.27 (0.92-1.75) | 1.31 (0.95-1.80) |
| Aripiprazole | 1.19 (0.55-2.56) | 1.21 (0.56-2.62) | 1.12 (0.52-2.44) | 1.03 (0.56-1.90) | 0.97 (0.53-1.79) | 1.06 (0.57-1.97) |
| Clozapine | **0.21 (0.05-0.83)** | **0.20 (0.05-0.83)** | **0.24 (0.06-0.97)** | 0.47 (0.11-1.89) | 0.43 (0.11-1.77) | 0.53 (0.13-2.19) |
| Other monotherapy | 1.14 (0.77-1.68) | 1.24 (0.84-1.86) | 1.35 (0.90-2.01) | **0.57 (0.36-0.92)** | **0.59 (0.36-0.96)** | 0.64 (0.39-1.05) |
| Polytherapy | 0.63 (0.35-1.11) | 0.65 (0.36-1.15) | 0.67 (0.37-1.19) | 0.73 (0.43-1.23) | 0.72 (0.42-1.21) | 0.74 (0.43-1.25) |
| **First diagnosed (ref in hospital)** |  |  |  |  |  |  |
| In outpatient care | 1.16 (0.93-1.44) | 1.19 (0.95-1.49) | 1.15 (0.91-1.44) | 1.27 (1.02-1.59) | **1.31 (1.05-1.65)** | 1.22 (0.97-1.54) |
| **Involuntary hospitalization (ref no)** |  |  |  |  |  |  |
| Yes | **1.33 (1.02-1.74)** | **1.36 (1.03-1.78)** | **1.46 (1.11-1.92)** | **1.42 (1.07-1.88)** | **1.46 (1.09-1.94)** | **1.48 (1.10-1.99)** |
| **Diagnosis during first year (ref F20/F25)** |  |  |  |  |  |  |
| Other | **1.56 (1.13-2.18)** | **1.60 (1.15-2.22)** | **1.68 (1.20-2.35)** | **1.72 (1.23-2.40)** | **1.69 (1.20-2.35)** | **1.66 (1.18-2.33)** |

1 Adjusted for sex, age and marital status

2 Adjusted for sex, age, marital status, antipsychotic treatment before diagnosis, first antipsychotic, involuntary hospitalization and diagnosis during first year

Bold font indicates statistical significance (p<0.05)